Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.46 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2099512 | 0.82 | CHRM2 (0.66) | CHRM2CHRM1CHRM3HTR1BTAAR1 | |
| SCHEMBL8549099 | 0.81 | DHFR (0.60) | DHFRCHRM2CHRM1CHRM3HTR1B | |
| SCHEMBL31288127 | 0.79 | HTR1B (0.50) | DHFRCHRM2CHRM1CHRM3HTR1B | |
| SCHEMBL29442823 | 0.78 | DHFR (0.57) | DHFRCHRM2CHRM1CHRM3TAAR1 | |
| SCHEMBL21384044 | 0.78 | DHFR (0.57) | DHFRCHRM2CHRM1CHRM3TAAR1 | |
| SCHEMBL25177952 | 0.78 | TAAR1 (0.43) | TAAR1IDO1MAOBLTA4H | |
| SCHEMBL2092574 | 0.77 | LTA4H (0.67) | CHRM2CHRM1CHRM3HTR1BTAAR1 | |
| SCHEMBL31739258 | 0.77 | LTA4H (0.67) | CHRM2CHRM1CHRM3HTR1BTAAR1 | |
| SCHEMBL7671410 | 0.76 | DHFR (0.48) | DHFRCHRM2CHRM1CHRM3HTR1B | |
| SCHEMBL14191204 | 0.75 | LTA4H (0.70) | CHRM2CHRM1CHRM3HTR1BTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4430047-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-118475580-A | Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof | 普罗根托斯治疗公司 | 2024-08-09 | — | — | CN | disclosed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PDGFRB, PDGFRA, PDGFA | DHFR 2186/4885CHRM2 4742/4885CHRM1 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.